Searched for
STELARA BIOSIMILAR
JNJ stock price today: Why Johnson & Johnson shares dropped despite strong 2026 forecast? Here's what investors are watchingJNJ stock price today: Johnson & Johnson stock saw a dip even as the company projected robust 2026 sales and profit figures. Legal issues, ...- Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IVBiocon Biologics has made strides in the healthcare sector by obtaining Health Canada’s approval for Yesintek and Yesintek IV, its latest a...
- Biocon plans $150-million capex in two yearsBiocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 mi...
- Biocon Biologics secures multiple market access agreements in US for YesintekBiocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 million lives. Mult...
- Johnson & Johnson earnings beat estimates on strong cancer drug salesJohnson & Johnson's first-quarter revenue and profit exceeded Wall Street expectations, driven by strong cancer drug sales. The company rai...
- Biocon shares in focus after successful results of Yesintek in Phase 3Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the last six month...
- Biocon shares in focus after subsidiary launches biosimilar alternative to Stelara in the USBiocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune conditions, offering ...
- Biocon shares zoom 4% as Jefferies upgrades to "hold" amid positive news inflow, sets Rs 400 targetBiocon share price: This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concern...
- Biocon Biologics gets US nod to launch Stelara biosimilarBiocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting autoimmune conditions...
- Biocon shares fall 6% after Q2 net profit dives 84%. What should investors do?Axis Securities and JM Financial both maintain 'Buy' ratings on Biocon, with target prices of Rs 370 and Rs 380, respectively. Biocon has a...
- Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, JapanBiocon Biologics has entered into a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & John...
- J&J Q2 Results: Pharma major beats Wall Street estimates on strong drug salesJohnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer ...
- J&J acquires experimental skin disorder drug for $1.25 billionNUMAB THERAPEUTICS-JOHNSON&JOHNSON/M&A (UPDATE 2, PIX)UPDATE 2-J&J acquires experimental skin disorder drug for $1.25 billion
- Stocks in news: Suven Pharma, MOIL, Adani stocks, ICICI Lombard, VedantaSuven Pharmaceuticals and Cohance Lifesciences signed a definitive agreement to merge their businesses, which will further strengthen the f...
- Biocon Biologics inks licence pact with Janssen for biosimilar productThe agreement licenses the company to launch in the US in February 2025, once approved by the US Food and Drug Administration(USFDA), Bioco...
- J&J Q4 Results: Profit edges past Street view after deals delay Stelara competitionJohnson & Johnson on Tuesday reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psor...
- Aurobindo Pharma subsidiary enters pact with BioFactura for biosimilar ustekinumabCuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma said it has entered into an exclusive license agreement with the US-based ...
- Stocks in news: Cyient DLM, HDFC Bank, Bajaj Auto, Hindustan ZincSuzlon Energy Ltd on Friday said its board has approved a proposal to raise up to Rs 2,000 crore. The company will explore various financia...
- Why Nithya Balasubramanian is gung-ho on Sun Pharma & Cipla“One gets different types of exposure with Sun Pharma and Cipla. For Sun, the capital allocation into US specialty is now bearing fruit. At...
- 'We have a conservative generic policy'Robert Sheroff, president, Global Pharmaceutical Supply Group (GPSG) spoke to Nina Mehta about the company’s plans in the country.
Load More
